[go: up one dir, main page]

BR0206160A - Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos - Google Patents

Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos

Info

Publication number
BR0206160A
BR0206160A BR0206160-0A BR0206160A BR0206160A BR 0206160 A BR0206160 A BR 0206160A BR 0206160 A BR0206160 A BR 0206160A BR 0206160 A BR0206160 A BR 0206160A
Authority
BR
Brazil
Prior art keywords
treatment
medicines
tnf antibodies
anemic patients
septic
Prior art date
Application number
BR0206160-0A
Other languages
English (en)
Inventor
Leah S Teoh
William T Barchuck
Steven A Fischkoff
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of BR0206160A publication Critical patent/BR0206160A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"USO DE ANTICORPOS ANTI-TNF COMO MEDICAMENTOS NO TRATAMENTO DE DISTúRBIOS SéPTICOS DE PACIENTES ANêMICOS". A presente invenção se refere ao tratamento de um paciente anêmico com níveis elevados de IL-6 pela administração de um antagonista de TNF. Também se refere ao tratamento sepse em um paciente pela administração de um antagonista de TNF.
BR0206160-0A 2001-05-25 2002-05-23 Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos BR0206160A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29381801P 2001-05-25 2001-05-25
PCT/US2002/018362 WO2002096461A1 (en) 2001-05-25 2002-05-23 Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients

Publications (1)

Publication Number Publication Date
BR0206160A true BR0206160A (pt) 2004-10-26

Family

ID=23130712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206160-0A BR0206160A (pt) 2001-05-25 2002-05-23 Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos

Country Status (5)

Country Link
US (1) US20030012786A1 (pt)
AR (1) AR034049A1 (pt)
BR (1) BR0206160A (pt)
PE (1) PE20021151A1 (pt)
WO (1) WO2002096461A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US6258562B1 (en) * 1996-02-09 2001-07-10 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US7087224B2 (en) 2000-10-31 2006-08-08 Amgen Inc. Method of treating anemia by administering IL-1ra
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
BR0312785A (pt) * 2002-07-19 2005-08-30 Abbott Biotech Ltd Tratamento de desordens relacionadas a tnf(alfa)
US20090280065A1 (en) * 2006-04-10 2009-11-12 Willian Mary K Uses and Compositions for Treatment of Psoriasis
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
MXPA06000965A (es) * 2003-07-25 2007-05-04 Silanes Sa De Cv Lab Administracion de fragmentos f(ab??)2 de anticuerpos anti-citocinas.
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
EP1807111A4 (en) * 2004-10-08 2009-05-27 Abbott Biotech Ltd SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
MX2007014440A (es) 2005-05-16 2008-02-11 Abbott Biotech Ltd Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
HRP20131112T1 (hr) * 2005-11-01 2014-01-03 Abbvie Biotechnology Ltd Postupak za odreä�ivanje uäśinkovitosti adalimumaba kod subjekata koji pate od ankilozantnog spondilitisa pomoä†u ctx-ii i mmp3 kao biomarkera
SG170837A1 (en) 2006-04-05 2011-05-30 Abbott Biotech Ltd Antibody purification
EP2007426A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
US20080118496A1 (en) * 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
WO2007120626A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of ankylosing spondylitis
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20090317399A1 (en) * 2006-04-10 2009-12-24 Pollack Paul F Uses and compositions for treatment of CROHN'S disease
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
US20100021451A1 (en) 2006-06-08 2010-01-28 Wong Robert L Uses and compositions for treatment of ankylosing spondylitis
US20080311043A1 (en) * 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
CN107243099A (zh) * 2006-06-30 2017-10-13 艾伯维生物技术有限公司 自动注射装置
JP2010507670A (ja) 2006-10-27 2010-03-11 アボツト・バイオテクノロジー・リミテツド 結晶性抗ｈＴＮＦα抗体
US8092998B2 (en) * 2007-05-31 2012-01-10 Abbott Laboratories Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
US20090110679A1 (en) * 2007-07-13 2009-04-30 Luk-Chiu Li Methods and compositions for pulmonary administration of a TNFa inhibitor
MX2010001488A (es) 2007-08-08 2010-03-01 Abbott Lab Composiciones y metodos para cristalizar anticuerpos.
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CN101965514A (zh) * 2008-01-03 2011-02-02 艾博特生物技术有限公司 预测化合物在治疗银屑病中的长期功效
NZ621174A (en) 2008-01-15 2015-09-25 Abbvie Deutschland Powdered protein compositions and methods of making same
NZ595885A (en) * 2009-04-29 2014-05-30 Abbvie Biotechnology Ltd Automatic injection device
CN102458469B (zh) * 2009-05-04 2014-12-24 艾伯维生物技术有限公司 人抗TNF-α抗体的稳定高蛋白质浓度制剂
MX2012007042A (es) * 2009-12-15 2012-11-06 Abbott Biotech Ltd Boton de disparo mejorado para dispositivo de inyeccion automatico.
CN103079594B (zh) 2010-06-03 2016-04-13 艾伯维生物技术有限公司 用于治疗化脓性汗腺炎(hs)的用途和组合物
AU2011325974B2 (en) 2010-11-11 2016-10-27 Abbvie Biotechnology Ltd. Improved high concentration anti-TNFalpha antibody liquid formulations
WO2012103141A1 (en) 2011-01-24 2012-08-02 Abbott Biotechnology Ltd. Automatic injection devices having overmolded gripping surfaces
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above

Also Published As

Publication number Publication date
PE20021151A1 (es) 2002-12-18
AR034049A1 (es) 2004-01-21
WO2002096461A1 (en) 2002-12-05
US20030012786A1 (en) 2003-01-16

Similar Documents

Publication Publication Date Title
BR0206160A (pt) Uso de anticorpos anti-tnf como medicamentos no tratamento de distúrbios sépticos de pacientes anêmicos
CY1111478T1 (el) Ενδειξη δοσολογιας προγεστερονης στην αντιμετωπιση τραυματικης εγκεφαλικης βλαβης
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BRPI0207700B8 (pt) mistura de conjugados monodispersa, composição farmacêutica, e, uso de uma mistura substancialmente monodispersa de um conjugado de polipeptídeo de insulina-oligômero
RU2007132181A (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
ATE510580T1 (de) Modulares stimulationsleitungsnetz
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
JP2006501240A5 (pt)
BR0316948A (pt) Composto, formulação farmacêutica, e, uso de um composto
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
BR0116481A (pt) Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6
NZ542866A (en) Compositions and methods for the therapy of inflammatory bowel disease
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
EA200400549A1 (ru) Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
BRPI0416882A (pt) composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
DE60222383D1 (de) Medikament zur verabreichung von amifostin und verwandten wirkstoffen
BR0114389A (pt) Terapia antitumor que inclui derivado de distamicina
BR0009380A (pt) Tratamento de câncer melhorado comtemozolomida
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
SE9902597D0 (sv) New use
GEP201606538B (en) Preoperative treatment of post operative pain
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]